It is looking likely that a third PARP inhibitor will soon be available in Europe to patients with ovarian cancer with Clovis Oncology Inc.'s announcement that it expects a recommendation for approval for Rubraca (rucaparib) from the EU's regulators at the end of next month.
The company says that following a meeting with the European Medicines Agency's Scientific Advisory Group Oncology last week and an...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

